Skip to main content
. 2022 Aug 1;14(8):529. doi: 10.3390/toxins14080529

Figure 1.

Figure 1

Indirect comparison between onabotulinumtoxinA and antibodies directed towards the signaling of CGRP. Anti-CGRP mAbs reduce the number of monthly headache days from baseline of 1.94 days and botulinum toxin of 1.86 days [36]. How much reduction the combination of the two treatments can afford is to be discovered. Data are expressed as monthly headache days (MHDs) difference over baseline ± upper/lower limit of confidence interval (CI).